Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have been assigned an average recommendation of “Hold” from the eighteen research firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $21.30.

A number of equities analysts have recently commented on ACOR shares. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price (down previously from $34.00) on shares of Acorda Therapeutics in a report on Wednesday, January 17th. Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Acorda Therapeutics in a report on Tuesday, January 9th. Piper Jaffray Companies reiterated a “neutral” rating and issued a $22.00 target price on shares of Acorda Therapeutics in a report on Tuesday, November 28th. Finally, TheStreet cut Acorda Therapeutics from a “c-” rating to a “d+” rating in a report on Friday, November 17th.

Acorda Therapeutics (ACOR) traded up $0.35 during midday trading on Friday, reaching $27.55. The company’s stock had a trading volume of 1,115,900 shares, compared to its average volume of 1,152,564. The stock has a market cap of $1,290.00, a PE ratio of -22.77 and a beta of 1.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40. Acorda Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.26). The firm had revenue of $141.07 million for the quarter, compared to analysts’ expectations of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.04) EPS. equities analysts predict that Acorda Therapeutics will post 0.02 EPS for the current fiscal year.

In related news, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total transaction of $226,856.50. Following the completion of the sale, the insider now directly owns 33,150 shares of the company’s stock, valued at approximately $680,569.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Lawrence sold 31,000 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $27.58, for a total value of $854,980.00. Following the sale, the insider now directly owns 5,275 shares of the company’s stock, valued at $145,484.50. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. Strs Ohio lifted its stake in shares of Acorda Therapeutics by 11.3% during the 4th quarter. Strs Ohio now owns 41,300 shares of the biopharmaceutical company’s stock worth $885,000 after acquiring an additional 4,200 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Acorda Therapeutics during the 4th quarter valued at $537,000. Schwab Charles Investment Management Inc. raised its position in Acorda Therapeutics by 7.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 302,836 shares of the biopharmaceutical company’s stock valued at $6,496,000 after purchasing an additional 20,148 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Acorda Therapeutics during the 3rd quarter valued at $541,000. Finally, Convergence Investment Partners LLC bought a new stake in Acorda Therapeutics during the 3rd quarter valued at $1,294,000.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/01/23/analysts-set-acorda-therapeutics-inc-acor-target-price-at-21-30.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.